CDKN2A and invasive carcinoma: Concerning pancreatic tumors, the CDKN2A/p16INK4A gene is inactivated in 95% of invasive carcinomas, 40% by homozygous deletion, 40% by an intragenic mutation coupled with loss of the second allele and 10–15% of cases by gene promoter hypermethylation.